ReviewCritical reviews in therapeutic drug carrier systems2007
Gene modulation for treating liver fibrosis.
Review in Critical reviews in therapeutic drug carrier systems, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- 20(S)- Protopanaxadiol suppresses hepatic stellate cell activation via WIF1 demethylation-mediated inactivation of the Wnt/β-catenin pathway.Journal of ginseng research · 2023Article
- Therapeutic interventions of acute and chronic liver disorders: A comprehensive review.World journal of hepatology · 2023Review
- Transcriptional regulation of alcohol induced liver fibrosis in a translational porcine hepatocellular carcinoma model.Biochimie · 2021Article
- siRNA- and miRNA-based therapeutics for liver fibrosis.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Targeted Delivery of an siRNA/PNA Hybrid Nanocomplex Reverses Carbon Tetrachloride-Induced Liver Fibrosis.Advanced therapeutics · 2019Article
- The Forkhead box F1 transcription factor inhibits collagen deposition and accumulation of myofibroblasts during liver fibrosis.Biology open · 2019Article
- Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells.Nanomedicine : nanotechnology, biology, and medicine · 2018Article
- Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients.African health sciences · 2017Observational
- Silencing of α-complex protein-2 reverses alcohol- and cytokine-induced fibrogenesis in hepatic stellate cells.Liver research (Beijing, China) · 2017Article
- Discovery of Aptamer Ligands for Hepatic Stellate Cells Using SELEX.Theranostics · 2017Article
- Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- Discovery of Peptide ligands for hepatic stellate cells using phage display.Molecular pharmaceutics · 2015Article
- Delivery and targeting of miRNAs for treating liver fibrosis.Pharmaceutical research · 2015Review
- Anti-fibrotic effects of the Masson pine pollen aqueous extract on hepatic fibrosis rat model.International journal of clinical and experimental pathology · 2015Article
- Pathogenesis of liver cirrhosis.World journal of gastroenterology · 2014Review
- Development of streptavidin-based nanocomplex for siRNA delivery.Molecular pharmaceutics · 2013Article
- Inhibition of hepatocellular carcinoma growth and angiogenesis by dual silencing of NET-1 and VEGF.Journal of molecular histology · 2013Article
- Multiplex transcriptional analysis of paraffin-embedded liver needle biopsy from patients with liver fibrosis.Fibrogenesis & tissue repair · 2012Article
- PCBP2 siRNA reverses the alcohol-induced pro-fibrogenic effects in hepatic stellate cells.Pharmaceutical research · 2011Article
- Targeted TFO delivery to hepatic stellate cells.Journal of controlled release : official journal of the Controlled Release Society · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Despite tremendous progress in our understanding of fibrogenesis, injury stimuli process, inflammation, and hepatic stellate cell (HSC) activation, there is still no standard treatment for liver fibrosis. Delivery of small molecular weight drugs, proteins, and nucleic acids to specific liver cell types remains a challenge due to the overexpression of extracellular matrix (ECM) and consequent closure of sinusoidal gaps. In addition, activation of HSCs and subsequent release of inflammatory cytokines and infiltration of immune cells are other major obstacles to the treatment of liver fibrosis. To overcome these barriers, different therapeutic approaches are being investigated. Among them, the modulation of certain aberrant protein production is quite promising for treating liver fibrosis. In this review, we describe the mechanism of antisense, antigene, and RNA interference (RNAi) therapies and discuss how the backbone modification of oligonucleotides affects their in vivo stability, biodistribution, and bioactivity. Strategies for delivering these nucleic acids to specific cell types are discussed. This review critically addresses various insights developed with each individual strategy and for multipronged approaches, which will be helpful in achieving more effective outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.